Renovo Concepts, Inc.
Renovo Concepts, Inc. is a medical device company established in 2017 and headquartered in San Antonio, Texas. The company is dedicated to developing innovative therapies for traumatic injuries, particularly traumatic brain injuries (TBI), through its Mechanical Tissue Resuscitation (MTR™) technology. MTR™ actively removes excess fluids from damaged tissues to mitigate secondary injury effects, offering a new therapeutic modality in a field with little recent innovation. The company aims to improve clinical outcomes, reduce hospital stays, and expand the market for TBI treatment.
Industries
Nr. of Employees
small (1-50)
Renovo Concepts, Inc.
12500 Network Blvd., Suite 207, San Antonio, TX 78249
Patents
Products
Gen 1 brain negative-pressure therapy device
A clinical-stage vacuum delivery platform with a cranial-surface manifold intended to remove excess interstitial fluid and reduce secondary injury after traumatic brain injury.
Gen 1 brain negative-pressure therapy device
A clinical-stage vacuum delivery platform with a cranial-surface manifold intended to remove excess interstitial fluid and reduce secondary injury after traumatic brain injury.
Services
Conduct and/or sponsor animal-model experiments to evaluate physiological effects, injury volume reduction and functional recovery after application of negative-pressure therapy.
Management of Phase I first-in-human trial activities including site coordination, patient enrollment planning and engagement of external study management partners.
Development, prototyping and manufacturing of a negative-pressure therapy platform and associated organ-surface manifolds aimed at clinical application.
Establishment and management of quality assurance and regulatory documentation to support device development and regulatory submissions.
Conduct and/or sponsor animal-model experiments to evaluate physiological effects, injury volume reduction and functional recovery after application of negative-pressure therapy.
Management of Phase I first-in-human trial activities including site coordination, patient enrollment planning and engagement of external study management partners.
Development, prototyping and manufacturing of a negative-pressure therapy platform and associated organ-surface manifolds aimed at clinical application.
Establishment and management of quality assurance and regulatory documentation to support device development and regulatory submissions.
Expertise Areas
- Negative-pressure therapeutic approaches for internal organs
- Preclinical animal model research (rodent, swine)
- Medical device design and prototyping
- Clinical trial planning and execution (First-in-Human/Phase I)
Key Technologies
- Controlled sub-atmospheric (negative) pressure delivery
- Organ-surface manifold interfaces for vacuum application
- In vivo blood flow measurement (laser Doppler)
- Electroencephalography (EEG)
News & Updates
Renovo Concepts, Inc. announced the appointment of Brad Mathis as CEO to lead the company's commercialization efforts. The company is preparing for first-in-human clinical trials of its MTR™ device for traumatic brain injury.
The company received FDA approval to conduct a Phase I clinical trial of its MTR™ device for TBI, involving nine subjects across two sites.
Research on using MTR™ to treat spinal cord injuries in animal models.
Study demonstrating the effectiveness of MTR™ in reducing injury volume and hemorrhage in a swine model.
Research on using MTR™ as a new approach to treat TBI.
Study on using MTR™ for treating myocardial infarction.
Renovo Concepts, Inc. announced the appointment of Brad Mathis as CEO to lead the company's commercialization efforts. The company is preparing for first-in-human clinical trials of its MTR™ device for traumatic brain injury.
The company received FDA approval to conduct a Phase I clinical trial of its MTR™ device for TBI, involving nine subjects across two sites.
Research on using MTR™ to treat spinal cord injuries in animal models.
Study demonstrating the effectiveness of MTR™ in reducing injury volume and hemorrhage in a swine model.
Research on using MTR™ as a new approach to treat TBI.
Study on using MTR™ for treating myocardial infarction.